KY-1044（Cat No.:I042179）is an investigational monoclonal antibody that targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on immune cells like T-cells and NK cells. TIGIT suppresses immune responses, allowing tumors to evade immune detection. By inhibiting TIGIT, KY-1044 aims to restore and enhance the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors, in combination with other therapies, to improve patient outcomes through immune system modulation.
